Supplementary Figure S2 from A Phase 2 Study of the MEK1/2 Inhibitor Luvometinib in Patients with Extracranial Arteriovenous Malformations

Authors:

Open Access

Waterfall plot of the best efficacy of target lesion volume change from baseline by gene mutation assessed by (a) DSA and (b) MRI.